Can-Fite BioPharma has secured a US patent for Namodenoson, its lead drug candidate, for use as an anti-obesity treatment.

Adenosine is a short-acting endogenous molecule that is a purine nucleoside. The half-life is 6 seconds. Adenosine receptor activation results in multiple different actions depending on the location.

For many people, a cup of coffee is an essential part of the morning routine - but it turns out that our bodies can become ...

We have been exploring the potential of the neuromodulator, adenosine, to reduce excessive dopamine signaling that contributes to the development and persistence of psychostimulant abuse. Dopamine’s ...

The Namodenoson oral drug is well positioned in the field of anti-obesity agents due to its activity and favorable safety profile Ramat Gan, ...

The reaction product is adenosine diphosphate (ADP), and the phosphate group either ends up as orthophosphate (HPO 4) or attached to another molecule (e.g. an alcohol). Even more energy can be ...

A recent study by researchers at the University of Florence and collaborators has demonstrated the efficacy of MRS-3997, a dual adenosine A2A/A2B receptor agonist, in reducing brain damage and ...

CD39-Targeted Therapies Near Key Milestones, First Approval Projected by 2029Dublin, Jan. 28, 2025 (GLOBE NEWSWIRE) -- The "CD39 Targeted Therapies Clinical Trials, Therapeutic Approaches & Market ...

The activation of the adenosine A2A receptor, which is mediated by the inhibition of adenosine A1 receptor, has been associated with depression-like behavior and anhedonia. High levels of cortisol, ...

ATP (adenosine triphosphate) is the energy-carrying molecule used in cells because it can release energy very quickly. Energy is released from ATP when the end phosphate is removed. Once ATP has ...